EAM
RXDX
Eventide Asset Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-670,020
| Closed | -$71.9M | – | 164 |
|
|
2023
Q1 | $71.9M | Sell |
670,020
-362,918
| -35% | -$38.9M | 1.32% | 22 |
|
|
2022
Q4 | $114M | Sell |
1,032,938
-1,636,317
| -61% | -$180M | 2.24% | 7 |
|
|
2022
Q3 | $158M | Sell |
2,669,255
-563,445
| -17% | -$33.2M | 3.1% | 1 |
|
|
2022
Q2 | $91.3M | Hold |
3,232,700
| – | – | 1.95% | 14 |
|
|
2022
Q1 | $122M | Sell |
3,232,700
-509,807
| -14% | -$19.3M | 1.91% | 15 |
|
|
2021
Q4 | $145M | Buy |
3,742,507
+28,475
| +0.8% | +$1.1M | 1.85% | 13 |
|
|
2021
Q3 | $85.1M | Hold |
3,714,032
| – | – | 1.12% | 34 |
|
|
2021
Q2 | $88.2M | Hold |
3,714,032
| – | – | 1.18% | 32 |
|
|
2021
Q1 | $65.6M | Buy |
+3,714,032
| New | +$65.6M | 0.97% | 39 |
|